Market capitalization | $6.23m |
Enterprise Value | $530.00k |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 0.58 |
Sales growth (TTM) Sales growth | -100.00% |
Turnover (TTM) Turnover | $0.00 |
EBIT (operating result TTM) EBIT | $-10.37m |
Free cash flow (TTM) Free cash flow | $-16.90m |
As a free StocksGuide basic user, you can view the scores for all 6,953 shares worldwide.
1 Analyst has issued a forecast Cyclerion Therapeutics,Inc.:
1 Analyst has issued a forecast Cyclerion Therapeutics,Inc.:
Mar '24 | |
Current assets | 6.01 6.01 |
Fixed assets | 5.35 5.35 |
Total assets | 11 11 |
Mar '24 | |
Equity | 9.92 9.92 |
Debt capital | 1.44 1.44 |
Total capital | 11 11 |
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for serious and orphan diseases, through the use of soluble guanylate cyclase (sGC) pharmacology. Its product pipeline includes several sGC stimulators, a small molecules that act synergistically with nitric oxide on sGC to boost production of cyclic guanosine monophosphate (cGMP). The company was founded on September 6, 2018 and is headquartered in Cambridge, MA.
Head office | United States |
CEO | Peter Hecht |
Employees | 1 |
Founded | 2018 |
Website | www.cyclerion.com |
StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.